Is Xencor (XNCR) overvalued or fairly valued?

MarketChacha shows Xencor's valuation in context — a forward P/E of about -7.5, a price-to-book of about 3.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Xencor's revenue?

Xencor reported revenue of $125.6M for FY2025, with net profit of $-91.9M, per official filings.

What is the share price of Xencor (XNCR)?

Xencor last traded at $26.61 (-0.0% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Xencor

XNCR · NYSE · Healthcare · United States

Snapshot

TickerXNCR

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees260

HeadquartersPasadena, United States

Websitewww.xencor.com

Filings tracked19

About Xencor

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Who owns it

Insiders1.2%
Institutions98.8%
Public & other0.0%

301 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.18.36%
Primecap Management Company13.69%
BVF Inc.9.59%
RTW Investments LP9.12%
RA Capital Management, L.P.7.09%
State Street Corporation6.66%
Vanguard Capital Management LLC4.41%
TCG Crossover Management, LLC3.30%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of -14.5% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-76.2% → -73.2%

Margin has expanded by about 3.0 points — the business is getting more profitable.

Return on equity-14.5%

Latest ROE of -14.5% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $30.2M · EPS -0.78

Est. earnings growth -765.1%

Next fiscal year

Rev $125.6M · EPS -3.50

Est. earnings growth -12.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$125.6M

Net margin

-73.2%

ROE

-14.5%

Revenue CAGR (2y)

-15.2%

EPS (FY2025)

-1.24

Net profit (FY2025)

$-91.9M

Ask MarketChacha about XNCR

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$125.6M	$-91.9M	-1.24	-73.2%	-14.5%
FY2024	$110.5M	$-232.6M	-3.58	-210.5%	-34.3%
FY2023	$174.6M	$-133.1M	-2.20	-76.2%	-20.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$51.2M	$-21.7M	-0.29	-42.4%
2026Q1	$4.5M	$-128.9M	-1.71	-2854.7%
2025Q3	$21.0M	$-6.0M	-0.08	-28.7%
2025Q2	$43.6M	$-30.8M	-0.41	-70.7%
2025Q1	$32.7M	$-48.4M	-0.66	-147.9%
2024Q3	$17.8M	$-46.3M	-0.72	-260.1%
2024Q2	$23.9M	$-67.3M	-1.09	-281.7%
2024Q1	$16.0M	$-73.4M	-1.20	-459.1%
2023Q3	$59.2M	$-24.3M	-0.40	-41.0%
2023Q2	$45.5M	$-22.0M	-0.37	-48.2%
2023Q1	$19.0M	$-60.8M	-1.02	-320.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Material agreement, Results of operations, Reg FD disclosure, Exhibits
SEC7/29/2026material
8-K — Shareholder vote results
SEC6/18/2026material
8-K — Results of operations, Exhibits
SEC5/6/2026material
10-Q filing
SEC5/6/2026
8-K — Reg FD disclosure, Exhibits
SEC5/5/2026material
8-K — Executive/director change, Exhibits
SEC4/27/2026material
8-K — Termination of agreement
SEC3/9/2026material
8-K — Reg FD disclosure, Exhibits
SEC3/4/2026material
8-K — Results of operations, Exhibits
SEC2/25/2026material
10-K filing
SEC2/25/2026
8-K — Results of operations, Exhibits
SEC1/8/2026material

2025

8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Reg FD disclosure, Exhibits
SEC10/24/2025material
8-K — Results of operations, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025
8-K — Executive/director change, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.